REDCURE Registry for Chronic Kidney Disease (CKD) Anemia (REDCURE)

January 15, 2026 updated by: Nabiqasim Industries (Pvt) Ltd

Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

384

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients with Chronic Kidney Disease (CKD) anemia requiring anemia treatment

Description

Inclusion Criteria:

  • Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)

    • Patients on hemodialysis (HD) or peritoneal dialysis (PD)
    • Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent

Exclusion Criteria

  1. Acute Kidney Injury (AKI) without underlying chronicity
  2. Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
  3. Refusal or inability to provide consent
  4. Current enrollment in an interventional trial that restricts real-world data collection
  5. Life expectancy < 3 months, where follow-up is not feasible
  6. Known contraindications to Daprodustat as per local prescribing information

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Daprodustat arm for CKD anemia patients
Drug: Daprodustat
Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum hemoglobin levels
Time Frame: 3 months
Hemoglobin response to therapy
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of MACE ( Major Adverse Cardiovascular Events)
Time Frame: 3 months

MACE events:

  • Unstable angina requiring hospitalization
  • Non-fatal MI
  • Non-fatal stroke

  • Cardiovascular death

    • Other adverse events

    • Hospitalization episodes

      . Mortality

    • Optional patient-reported outcomes (fatigue, functional status)
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nabiqasim Industries (Pvt) Ltd

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 30, 2026

Primary Completion (Estimated)

January 30, 2027

Study Completion (Estimated)

May 31, 2027

Study Registration Dates

First Submitted

January 8, 2026

First Submitted That Met QC Criteria

January 8, 2026

First Posted (Estimated)

January 16, 2026

Study Record Updates

Last Update Posted (Actual)

January 20, 2026

Last Update Submitted That Met QC Criteria

January 15, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NQ/DP/JES/Reg-006

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on CKD Anemia

Clinical Trials on Daprodustat

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe